Haemonetics price target lowered to $104 from $108 at Needham

Needham analyst Mike Matson lowered the firm’s price target on Haemonetics (HAE) to $104 from $108 and keeps a Buy rating on the shares. The firm is adjusting its model after the company completed the sale of its whole blood assets to GVS, S.p.A, the analyst tells investors in a research note. Needham is also cutting its FY26 EPS view by 22c to $4.99, though the firm expects Haemonetics to sustain mid- to high-single digit growth, driven by high-single digit or better non-CSL Plasma growth and mid-teens or better Hospital growth.